GlaxoSmithKline ($GSK) put up $50 million of a $250 million life sciences fund, assembled by San Mateo, CA-based Sanderling Ventures, to help fill a geographic gap in their strategy to seed new biotech startups. Report
| SPONSORED BY: Appian | Wednesday, August 12th | 11am ET / 8am PT
Pharma companies can employ several strategies for obtaining expedited approvals-including, in some cases, acquiring them from other companies. This webinar will feature regulatory experts from the pharma industry who can provide tips on navigating these programs. Register Today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!